Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Core Insights - Labcorp has expanded its molecular residual disease (MRD) portfolio to enhance early detection of cancer recurrence, introducing Labcorp Plasma Detect ID and Labcorp Plasma Detect Genome tests for specific cancer stages [1][7]. Group 1: MRD Testing and Cancer Recurrence - Cancer recurrence rates are significant, with approximately 35% of stage III colon cancer patients and 10% to 40% of stage I-III breast cancer patients experiencing recurrence post-treatment [2]. - MRD testing detects circulating tumor DNA (ctDNA) in the bloodstream, allowing for earlier detection of recurrence, potentially months before traditional imaging methods [3][8]. - The Labcorp Plasma Detect tests can detect ctDNA down to a limit of detection (LOD95) of 0.005%, enabling oncologists to tailor surveillance strategies for patients [3]. Group 2: Clinical Utility and Research - Labcorp's expanded portfolio supports personalized and proactive cancer care, providing clinicians with advanced tools for tracking molecular residual disease [4]. - Ongoing and completed clinical studies demonstrate the utility of Labcorp Plasma Detect in monitoring disease progression and predicting long-term outcomes [4]. - Recent peer-reviewed publications have highlighted the effectiveness of Labcorp Plasma Detect in patients with diffuse pleural mesothelioma and head and neck cancer, reinforcing the importance of MRD testing in personalized cancer care [4]. Group 3: Comprehensive Oncology Solutions - Labcorp's offerings span the entire cancer care continuum, from screening and diagnosis to therapy selection and monitoring [5]. - The company collaborates with oncologists, health systems, and biopharma companies to drive precision medicine and improve patient outcomes globally [5]. - Labcorp performs over 700 million tests annually and has supported more than 75% of new drugs approved by the FDA in 2024 [6].